Globally Aggregated Testing Yield, Linkage to Treatment, Viral Load Coverage, and Viral Load Suppression for International and Local Partners in FY2019 and FY2020a
| International Partners | Local Partners | |||
|---|---|---|---|---|
| FY2019 | FY2020 | FY2019 | FY2020 | |
| Testing yield (no. of HIV-positive test results/ total no. of HIV tests) | 3.8% (583,166/1,5217,356) | 4.5% (459,375/1,0284,268) | 4.5% (627,857/1,3860,152) | 4.5% (520,299/11,645,984) |
| Linkage to treatment (no. of clients with HIV-positive test results initiating treatment/ total no. of HIV+ tests) | 79.2% (462,159/5,831,660) | 85.8% (394,243/459,375) | 91.0% (571,543/627,857) | 95.2% (495,410/520,299) |
| Viral load coverage (no. of ART patients with a VL result within the last year/no. of patients on treatment 6 months prior) | 78.3% (1,559,602/1,991,610) | 77.5% (1,642,612/2,118,905) | 80.1% (2,470,359/3,084,502) | 71.2% (2,657,202/3,732,035) |
| Viral load suppression (no. patients on ART who received a viral load test and are virally suppressed/ no. of patients currently on ART who received a viral load test) | 88.6% (1,382,535/1,559,602) | 91.6% (1,505,228/1,642,612) | 91.7% (2,264,823/2,470,359) | 92.8% (2,466,371/2,657,202) |
Abbreviation: ART, antiretroviral therapy; FY, fiscal year; VL, viral load.
↵aThese statistics only include partners reporting those currently on treatment (i.e., those partners providing treatment services). The table includes both the calculated indicators (%) and the underlying raw numbers for each calculation. Regional partners are counted as local in both FY2019 and FY2020. To be determined awards are excluded from calculated indicator calculations.